Načítá se...
A85 EFFICACY AND SAFETY OF DOSE ADJUSTMENT AND DELAYED RESPONSE TO USTEKINUMAB IN MODERATE–SEVERE CROHN’S DISEASE: RESULTS FROM THE IM-UNITI MAINTENANCE STUDY
AIMS: Ustekinumab (UST) has been shown to induce and maintain clinical response and remission in moderate-severe Crohn’s disease (CD) in 2 induction (UNITI-1 & 2) and 1 maintenance (IM-UNITI) randomized, PBO-controlled Phase 3 trials. We evaluated the efficacy of UST in 2 additional groups in IM...
Uloženo v:
| Vydáno v: | J Can Assoc Gastroenterol |
|---|---|
| Hlavní autoři: | , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Oxford University Press
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6507553/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwy008.086 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|